July 2, 2015
Reduced body weight and improved metabolic control were found with once-daily subcutaneous Saxenda as an add-on to diet and exercise, according to recent study findings published in The New England Journal of Medicine.
Xavier Pi-Sunyer, MD, of Columbia University Medical Center, and colleagues conducted a 56-week, double blind study to evaluate 3,731 patients aged 18 years or older without type 2 diabetes and a BMI of at least 30 kg/m2 or a BMI of at least 27 kg/m2 if they had treated or untreated dyslipidemia or hypertension to determine the effect of Saxenda (liraglutide, Novo Nordisk) on weight management. Participants were randomly assigned to 3 mg once-daily subcutaneous liraglutide (n = 2,487) or placebo (n = 1,244) with counseling on lifestyle modification. Change in body weight and rate of patients losing at least 5% and more than 10% of their initial body weight were the primary endpoints.